Page number 9
5 Investor presentation First nine months of 2022 Sales growth of 16% driven by bo Reported geographic sales split for first nine months of 2022 DKK billion Insulin Obesity care GLP-1 Rare disease Other diabetes Growth at CER 70 22% 60 50 40 30 20 10 0 NAO 11% International Operations 13% 22% -5% IO EMEA China RoW 1 ‘Other diabetes’ is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of W Note: Unless otherwise specified, sales growth rates are at CER
Page number 10
oth operating units Novo Nordisk ® Reported therapy area sales and growth for first nine months of 2022 DKK billion North America Operations Growth at CER International Operations 150 16% 44% -11% 75% 2% 100 11% 50 22% 0 Total 1 55% 39% IO NAO -7% -20% IO NAO 73% 77% IO 4% NAO -3% GLP-1 Insulin Obesity care Rare disease World; NAO: North America Operations
